BridgeBio Pharma, Inc. (BBIO)

Market Cap	5.06B
Revenue (ttm)	218.60M
Net Income (ttm)	-538.26M
Shares Out	187.13M
EPS (ttm)	-3.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	851,638
Open	27.40
Previous Close	26.70
Day's Range	26.61 - 27.84
52-Week Range	21.62 - 44.32
Beta	1.06
Analysts	Strong Buy
Price Target	46.83 (+73.12%)
Earnings Date	Aug 5, 2024

About BBIO

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 550
• Stock Exchange: NASDAQ
• Ticker Symbol: BBIO

Financial Performance

In 2023, BBIO's revenue was $9.30 million, a decrease of -88.02% compared to the previous year's $77.65 million. Losses were -$643.20 million, 33.7% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price forecast is $46.83, which is an increase of 73.12% from the latest price.

Price Target

$46.83

(73.12% upside)

Analyst Consensus: Strong Buy